Navigation Links
Cerulean Pharma to Present Data on CRLX101's HIF-1a Inhibition at the American Association for Cancer Research Annual Meeting
Date:4/4/2013

X101 in combination with anti-angiogenic agents are very impressive. I am excited that we can bring this combination hypothesis into the clinic, and I am encouraged by the results of this trial to date," said Dr. Keefe. "CRLX101's favorable safety profile is encouraging, and its ability to provide durable inhibition of HIF-1a could increase the benefit that anti-angiogenic agents provide to patients."

In addition, Cerulean scientists will participate in the following sessions at AACR:

  • CRLX101, a nanopharmaceutical in phase 2 clinical trials, is synergistic with antiangiogenic treatment through HIF-1a inhibition in an ovarian cancer xenograft model (April 7, 1:00 – 5:00 pm): Douglas Lazarus , director of biology at Cerulean, will present a poster on the improved efficacy of antiangiogenic drugs when combined with CRLX101.
  • Nanotechnology Approaches to the Treatment of Cancer (April 7, 1:00 – 3:00 pm): Dr. Scott D. Eliasof , vice president of research at Cerulean, will participate in a panel discussion led by Mark Davis of the California Institute of Technology on the advantages of using nanoparticles such as CRLX101 for the treatment of cancer, including how nanotechnology enabled the creation of the first clinically relevant HIF-1a inhibitor.

About CRLX101

CRLX101 is an investigational anti-cancer agent that is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1α. CRLX101 is a dynamically tumor-targeted nanopharmaceutical designed to concentrate in tumors and release its payload, camptothecin, over an extended period of time, prolonging drug exposure at the site of action. Anti-tumor activity has been observed across a wide range of cancers in animal models and in seven clinical trials. CRLX101 is currently in Phase 2 clinical development. More informatio
'/>"/>

SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cerulean Pharmas Lead Candidate Selected as a "Top 10 Oncology Project to Watch"
2. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. Valeant Pharmaceuticals Provides Update to Recent Event
5. X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop Novel Therapeutic Antibodies For AMD
6. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
7. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
8. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
9. Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
10. Kentucky Health Cooperative To Partner With ProCare Rx For Pharmacy Benefit Management
11. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... 2010 STAAR Surgical Company (Nasdaq: STAA ... invasive ophthalmic products, today reported results for the third ... grew 6% to $13.2 million reflecting core product (IOLs ... decrease in defocused product revenue as compared to the ...
... Nov. 2, 2010 Kensey Nash Corporation (Nasdaq: ... investor conferences in November.   Michael Celano, ... presentation, at the Oppenheimer 21st Annual Healthcare Conference at ... at 2:10 p.m. (ET).  To hear the live webcast ...
Cached Medicine Technology:STAAR Surgical Reports Continued Double Digit Core Revenue Growth 2STAAR Surgical Reports Continued Double Digit Core Revenue Growth 3STAAR Surgical Reports Continued Double Digit Core Revenue Growth 4STAAR Surgical Reports Continued Double Digit Core Revenue Growth 5STAAR Surgical Reports Continued Double Digit Core Revenue Growth 6STAAR Surgical Reports Continued Double Digit Core Revenue Growth 7STAAR Surgical Reports Continued Double Digit Core Revenue Growth 8STAAR Surgical Reports Continued Double Digit Core Revenue Growth 9STAAR Surgical Reports Continued Double Digit Core Revenue Growth 10STAAR Surgical Reports Continued Double Digit Core Revenue Growth 11STAAR Surgical Reports Continued Double Digit Core Revenue Growth 12STAAR Surgical Reports Continued Double Digit Core Revenue Growth 13STAAR Surgical Reports Continued Double Digit Core Revenue Growth 14STAAR Surgical Reports Continued Double Digit Core Revenue Growth 15STAAR Surgical Reports Continued Double Digit Core Revenue Growth 16STAAR Surgical Reports Continued Double Digit Core Revenue Growth 17
(Date:7/10/2014)... cheeses and cakes that are just as tempting ... shelves, thanks to fresh insights into how proteins ... texture. , Funded by the Engineering and ... Heriot-Watt University and the University of Edinburgh has ... micro-particles and therefore closely mimic the behaviour of ...
(Date:7/9/2014)... 10, 2014) If you think winning is one of ... think again: Winning along with other mental bonuses ranked near ... falls into one of 11 big fun factors, according to ... all important when it comes to the "fun" factor, very ... what goes into this elusive conceptuntil now. , The results ...
(Date:7/9/2014)... For the first time, researchers have access to detailed ... uses health care. A new study, called Our Health ... unique challenges faced by urban Aboriginal people in Canada ... , The findings, published today in BMJ Open ... and the general population. , Researchers interviewed 554 First ...
(Date:7/9/2014)... had an aneurysm, she figured an invasive brain surgery and ... said Wakulich, who is 56 years old and lives in ... Then I met Dr. Bernard Bendok who told me about ... was something I didn,t even know was an option." , ... to evaluate the safety and effectiveness of the Microvention Inc. ...
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
Breaking Medicine News(10 mins):Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Urban Aboriginal people face unique health challenges 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Lung cancer study hints at new treatments 2
... April 24 Actavis Group, the,international generic pharmaceuticals ... a case study on the Company and its ... Actavis, ,Winning,formula," was presented in an MBA class ... will be made available to business,schools around the ...
... Was Served, -, LOS ANGELES, April 23 ... against Yolanda McGriff, a Los Angeles-,based healthcare worker who ... a low-income, disabled veteran. McGriff was arrested for,trespass-related violations ... employer, a man who lived in what used to ...
... Reflecting the growing concern,over health care costs and ... afford a comfortable retirement decreased over the past ... of the Retirement Confidence Survey(R),(RCS), according to just-released ... News Release, go to:, http://www.prnewswire.com/mnr/ebri/32335/ , The ...
... of image-guided ... therapy, PALO ALTO, Calif., April 23 Varian Medical,Systems ... than 60 orders for,its new RapidArc radiotherapy product for faster ... but have also come in from Europe and Asia,since the ...
... the voice of the,public, Hero Nutritionals, Inc. is launching ... adults. Hero Nutritionals, manufacturer of Yummi,Bears, the original gummy ... moms buying Yummi Bears, for an adult version of ... Yummi Bears is the,nation,s #1 & best tasting gummy ...
... using a bionic boot found that during walking, the ankle ... of energy compared to isolated muscles---in other words, the spring ... efficiently. , While much has been done measuring the efficiency ... measure the energy efficiency of a body part such as ...
Cached Medicine News:Health News:Harvard Business School Publishes a Case Study on Robert Wessman and Actavis 2Health News:Harvard Business School Publishes a Case Study on Robert Wessman and Actavis 3Health News:Case Dropped Against Healthcare Worker Who Was Arrested While Providing Care to an Elderly, Disabled Man in Los Angeles Home 2Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 2Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 3Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 4Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 2Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 3Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 4Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 5Health News:Hero Nutritionals Introduces a New Adult Vitamin for the Taste Buds 2Health News:The spring in your step is more than just a good mood 2
Intended for the quantitative determination of iron in serum. Reaction: Endpoint. Wavelength: 595 nm. Linearity: 500 g/dL (89.5 mol/L). Two vials, liquid reagents....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included....
Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma....
Medicine Products: